NORVIR TABLETS 100 MG [SIN14288P]
Active ingredients: NORVIR TABLETS 100 MG
Last updated 24 April 2026
Product Info
NORVIR TABLETS 100 MG
[SIN14288P]
Product information
Active Ingredient and Strength | RITONAVIR - 100 MG |
Dosage Form | TABLET, FILM COATED |
Manufacturer and Country | ABBVIE DEUTSCHLAND GMBH & CO. KG - GERMANY |
Registration Number | SIN14288P |
Licence Holder | ABBVIE PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | J05AE03 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
INDICATIONS AND USAGE
Ritonavir is indicated as a pharmacokinetic enhancer of co-administered protease inhibitors as part of antiretroviral combination therapy for the treatment of patients with HIV-1 infection.
Dosing
DOSAGE AND ADMINISTRATION
General Dosing Guidelines: Prescribers should consult the full prescribing information and clinical study information of protease inhibitors if they are co-administered with a reduced dose of ritonavir.
Ritonavir is no longer recommended in clinical practice at the antiretroviral dose of 1200 mg (600 mg twice daily).
When ritonavir tablets are used as a pharmacokinetic enhancer for another antiretroviral protease inhibitor up to a maximum daily dose of 200 mg, the Prescribing Information of the particular protease inhibitor should be consulted.
Adults
Tablets
When ritonavir is used as a pharmacokinetic enhancer for another antiretroviral protease inhibitor, the Prescribing Information of the particular protease inhibitor should be consulted. Ritonavir tablets should be swallowed whole and not chewed, broken or crushed.
Pediatric Patients
Ritonavir should be used in combination with other antiretroviral agents. When ritonavir is used as a pharmacokinetic enhancer for another antiretroviral protease inhibitor, the Prescribing Information of the particular protease inhibitor should be consulted. The highest tolerated dose should be used for maintenance therapy in combination with other antiretroviral agents.
The tablet formulation may not be suitable for paediatric use in some cases.
Contraindications
CONTRAINDICATIONS
Ritonavir is contraindicated in patients with known hypersensitivity to ritonavir or any of its formulation excipients.
When co-administering ritonavir with other protease inhibitors, see the full prescribing information for that protease inhibitor including contraindication information.
In vitro studies have demonstrated that ritonavir is a potent inhibitor of many cytochrome P450 mediated biotransformations. Based primarily on literature review, ritonavir is expected to produce large increases in the plasma concentrations of the drugs metabolized by cytochrome P450. Co-administration of ritonavir is contraindicated with the drugs listed in Table 1.
